ArticleFrontiers in cardiovascular medicine2025
Diagnostic value of platelet to high-density lipoprotein cholesterol ratio in abdominal aortic aneurysms.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The predictive value of platelet-to-high density lipoprotein cholesterol ratio and white blood cell-to-mean platelet volume ratio for coronary artery disease risk in STEMI patients.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Abdominal aortic aneurysm (AAA) is a disease with a relatively high mortality risk. Currently, diagnosis of AAA predominantly depends on imaging examinations, and there is an urgent need for simple and rapid screening biomarkers. The platelet to high-density lipoprotein cholesterol ratio (PHR) is an emerging biomarker reflects systemic inflammation and hypercoagulable states in cardiovascular diseases. The aim of this study is to elucidate the clinical significance of PHR in AAA. Methods: A total of 156 patients with AAA and 113 healthy controls were enrolled. Among them, 80 patients with AAA had concomitant thrombosis. Serum samples were collected upon admission to the hospital and before treatment. The equation for PHR calculation is: PHR = [platelet (1,000 cells/µl)/HDL-C (mmol/L)]. The optimal PHR cut-off was determined via ROC analysis, and logistic regression identified AAA predictors. Results: In this study, PHR level in patients with AAA was significantly higher than that of control group [127.00 (109.74, 163.42) vs. 192.35 (159.08, 231.66); <0.001]. Additionally, PHR value was even higher in AAA patients with thrombosis [161.80 (135.54, 193.41) vs. 220.61 (186.49, 262.27); <0.001]. ROC curve analysis revealed that PHR had a good predictive value for diagnosis of AAA, with an area under the curve (AUC) of 0.805. When it came to the diagnosis of AAA patients with thrombosis, the AUC of PHR was 0.814. Multivariate logistic regression analysis further demonstrated that PHR was an independent predictor in AAA (OR: 1.022, 95% CI: 1.012-1.031; Conclusion: PHR has good diagnostic value for AAA and can serve as a rapid screening indicator for its clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.